These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 1699628)

  • 1. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, cernilton. A double-blind, placebo-controlled study.
    Buck AC; Cox R; Rees RW; Ebeling L; John A
    Br J Urol; 1990 Oct; 66(4):398-404. PubMed ID: 1699628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cernilton for benign prostatic hyperplasia.
    Wilt T; Mac Donald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2000; (2):CD001042. PubMed ID: 10796739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WITHDRAWN: Cernilton for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2011 May; 2011(5):CD001042. PubMed ID: 21563128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia.
    MacDonald R; Ishani A; Rutks I; Wilt TJ
    BJU Int; 2000 May; 85(7):836-41. PubMed ID: 10792162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoramin in the treatment of prostatic bladder outflow obstruction.
    Stott MA; Abrams P
    Br J Urol; 1991 May; 67(5):499-501. PubMed ID: 1710162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S
    Int Urol Nephrol; 1996; 28(1):49-53. PubMed ID: 8738619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of Cernilton on benign prostatic hyperplasia].
    Ueda K; Jinno H; Tsujimura S
    Hinyokika Kiyo; 1985 Jan; 31(1):187-91. PubMed ID: 2581428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind randomized placebo-controlled study of Bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia.
    Zegarra L; Vaisberg A; Loza C; Aguirre RL; Campos M; Fernandez I; Talla O; Villegas L
    Int Braz J Urol; 2007; 33(4):493-500; discussion 501. PubMed ID: 17767753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost].
    Maekawa M; Kishimoto T; Yasumoto R; Wada S; Harada T; Ohara T; Okajima E; Hirao Y; Ohzono S; Shimada K
    Hinyokika Kiyo; 1990 Apr; 36(4):495-516. PubMed ID: 1696065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.
    Ramsay JW; Scott GI; Whitfield HN
    Br J Urol; 1985 Dec; 57(6):657-9. PubMed ID: 2417649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of different drugs on the treatment of benign prostate hyperplasia].
    Li NC; Wu SL; Jin J; Qiu SP; Kong CZ; Song YS; Ye ZQ; Sun G; Sun YH; Sun YC; Wang XF; Na YQ
    Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(14):947-50. PubMed ID: 17961376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction.
    Caine M; Perlberg S; Meretyk S
    Br J Urol; 1978 Dec; 50(7):551-4. PubMed ID: 88984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
    Tammela TL; Kontturi MJ
    J Urol; 1993 Feb; 149(2):342-4. PubMed ID: 7678871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation.
    Ronchi F; Margonato A; Ceccardi R; Rigatti P; Rossini BM
    Urol Res; 1982; 10(3):131-4. PubMed ID: 6182672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of Cernilton in benign prostatic hypertrophy].
    Hayashi J; Mitsui H; Yamakawa G; Suga A; Kai A; Shimabukuro T; Yanagi K; Fujisawa S; Takihara H; Kaneda Y
    Hinyokika Kiyo; 1986 Jan; 32(1):135-41. PubMed ID: 2421560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
    Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P
    Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.
    Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
    Int J Urol; 2014 Dec; 21(12):1258-62. PubMed ID: 25039474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of benign prostatic hyperplasia with phytosterols.
    Carbin BE; Larsson B; Lindahl O
    Br J Urol; 1990 Dec; 66(6):639-41. PubMed ID: 1702340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.